🇺🇸 Dupilumab - Discontinuation in United States

FDA authorised Dupilumab - Discontinuation on 28 March 2017

Marketing authorisations

FDA — authorised 28 March 2017

  • Application: BLA761055
  • Marketing authorisation holder: REGENERON PHARMACEUTICALS
  • Local brand name: DUPIXENT
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA

  • Status: approved

Dupilumab - Discontinuation in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Dupilumab - Discontinuation approved in United States?

Yes. FDA authorised it on 28 March 2017; FDA has authorised it.

Who is the marketing authorisation holder for Dupilumab - Discontinuation in United States?

REGENERON PHARMACEUTICALS holds the US marketing authorisation.